Computational Retinal Microvascular Biomarkers from an OCTA Image in Clinical Investigation

Biomedicines. 2024 Apr 15;12(4):868. doi: 10.3390/biomedicines12040868.

Abstract

Retinal structural and functional changes in humans can be manifestations of different physiological or pathological conditions. Retinal imaging is the only way to directly inspect blood vessels and their pathological changes throughout the whole body non-invasively. Various quantitative analysis metrics have been used to measure the abnormalities of retinal microvasculature in the context of different retinal, cerebral and systemic disorders. Recently developed optical coherence tomography angiography (OCTA) is a non-invasive imaging tool that allows high-resolution three-dimensional mapping of the retinal microvasculature. The identification of retinal biomarkers from OCTA images could facilitate clinical investigation in various scenarios. We provide a framework for extracting computational retinal microvasculature biomarkers (CRMBs) from OCTA images through a knowledge-driven computerized automatic analytical system. Our method allows for improved identification of the foveal avascular zone (FAZ) and introduces a novel definition of vessel dispersion in the macular region. Furthermore, retinal large vessels and capillaries of the superficial and deep plexus can be differentiated, correlating with retinal pathology. The diagnostic value of OCTA CRMBs was demonstrated by a cross-sectional study with 30 healthy subjects and 43 retinal vein occlusion (RVO) patients, which identified strong correlations between OCTA CRMBs and retinal function in RVO patients. These OCTA CRMBs generated through this "all-in-one" pipeline may provide clinicians with insights about disease severity, treatment response and prognosis, aiding in the management and early detection of various disorders.

Keywords: computational retinal microvasculature biomarkers (CRMB); optical coherence tomography angiography (OCTA); retinal imaging; retinal vein occlusion.

Grants and funding

This project is supported by grants from the National Natural Science Foundation of China, China (82174445) to L.X., the Midstream Research Programme for Universities, Hong Kong (MRP-092-17x) to K.C., Major Science and Technological innovation Project of the China Academy of Chinese Medical Sciences, China (CI2021A02606) to X.H., Dominant Disease Species-Hospital Preparation-New Drug R&D Special Project of the China Academy of Chinese Medical Sciences, China (ZZ15-XY-PT-09) to X.H., Major Science and Technological innovation Project of the China Academy of Chinese Medical Sciences, China (C12021A05107) to X.H.